GENEVA, April 1 -- SLBIGEN INC. (85, Songdogwahak-roYeonsu-guIncheon 21983), 주식회사 에스엘바이젠 (인천광역시연수구송도과학로 85), GI INNOVATION, INC. (A-1116, 167, Songpa-daeroSongpa-guSeoul 05855), (주)지아이이노베이션 (서울특별시송파구송파대로 167, 에이동 1116호) filed a patent application (PCT/KR2024/014224) for "NOVEL CANCER THERAPEUTIC AGENT COMPRISING ANTICANCER DNA VACCINE AND IMMUNE RESPONSE-ENHANCING FUSION PROTEIN" on Sep 20, 2024. With publicati...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.